RxDoctor Payments Data

Nadia Dussard Wright

Family · Clifton, NJNPI 1790307155

Payments from drug & device makers

$705in general payments, 2019–2025

Across 46 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$99
  • Novo Nordisk$92
  • Pfizer$70
  • GSK$67
  • AbbVie$49
  • Amgen$48
  • plus $278 from 11 others

What the payments were for

  • Food & beverage$705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$99
Novo Nordisk6$92
Pfizer5$70
GSK4$67
AbbVie4$49
Amgen3$48
Almatica Pharma LLC3$40
Novartis2$40
Jazz Pharmaceuticals Inc.3$39
Exact Sciences2$34
AstraZeneca2$28
Bayer1$22
Seqirus USA Inc1$19
Genentech USA, Inc.1$15
Althera Pharmaceuticals LLC1$14
E.r. Squibb & Sons, L.L.C.1$14
Athena Bioscience, LLC1$12

How this compares

$705 in reported general payments places this provider in the 70th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$844
Medicare patients
19
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$68,336
MounjaroTirzepatide43$46,158
OzempicSemaglutide39$38,039
JanuviaSitagliptin Phosphate21$23,883
JardianceEmpagliflozin14$22,400
FarxigaDapagliflozin Propanediol14$13,439
EntrestoSacubitril/Valsartan11$9,891
Rosuvastatin Calcium130$2,709
Atorvastatin Calcium153$2,046
Amlodipine Besylate212$1,624
Levothyroxine Sodium153$1,495
SynthroidLevothyroxine Sodium29$1,487
Metformin Hcl112$1,469
Metoprolol Succinate95$1,310
Insulin Lispro Kwikpen U-100Insulin Lispro12$1,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$68,33653 claims
Lilly USA, LLCMounjaro$99$46,15843 claims
Novo NordiskOzempic$92$38,03939 claims
AstraZenecaFarxiga$28$13,43914 claims
NovartisEntresto$40$9,89111 claims
AbbVieSynthroid$49$1,48729 claims
Almatica Pharma LLCSertraline Hcl$40$29727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,692 family providers in New Jersey.

Other family in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →